CXCL10 Informations sur la molécule
Molecule Name
C-X-C motif chemokine ligand 10
Alias de la molécule
C-X-C motif chemokine 10,10 kDa interferon gamma-induced protein,Gamma-IP10,IP-10,Small-inducible cytokine B10,CXCL10(1-73),CXCL10,INP10, SCYB10
Drug Development Progress
Nombre de médicaments cliniques2
Nombre de médicaments commercialisés0
Phase de R&D la plus avancéePhase 2 Clinical
Alias de la cible
Protein 10 From Interferon (Gamma)-Induced Cell Line，CXCL10，INP10，SCYB10，C-X-C motif chemokine 10，10 kDa interferon gamma-induced protein，IP-10，C-X-C Motif Chemokine Ligand 10，Small Inducible Cytokine Subfamily B (Cys-X-Cys)， Member 10，Chemokine (C-X-C Motif) Ligand 10，Small-Inducible Cytokine B10，Chemokine CXCL10，Interferon-Inducible Cytokine IP-10，Gamma IP10，Gamma-IP10，GIP-10，IFI10，Crg-2，Mob-1，C7
Contexte de la molécule
C-X-C Motif Chemokine Ligand 10 (CXCL10) is a pro-inflammatory chemokine secreted by a wide spectrum of cells. It is involved in multiple mechanisms and reported to have pleiotropic effects, including immune cell migration and attraction to inflammation sites, angiogenesis, and cancer cell growth. CXCL10 is produced by pancreatic islet cells upon inflammatory stress and is specifically recognized by C-X-C Motif Chemokine Receptor 3 (CXCR3) which is expressed by activated T-lymphocytes and other immune cells.
CXCL10 Liste de produits
You Have Viewed 0 Of 0 Results
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| JT-02 (JYANT Technologies) | JT-02 | Phase 2 Clinical | Jyant Technologies | Inflammatory Bowel Diseases | Details |
| NG-641 | EnAd-FAP-BiTE; EnAd-FAP-Tac; NG-641; NG-aFAP | Phase 1 Clinical | Akamis Bio Ltd | Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Squamous Cell Carcinoma of Head and Neck | Details |